MedTrace Logo

Effect of GLP-1 Receptor Agonists on Body Composition in Obesity: The Role of Dietary Protein Consumption in Muscle Mass Maintenance

NCT07495904 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2026-04-02

No results posted yet for this study

Summary

This study investigates how weight-loss medications, specifically GLP-1 receptor agonists, affect body composition, with a special focus on preserving muscle mass in adults with obesity. While these medications are highly effective for weight loss, they can sometimes lead to an unwanted loss of valuable muscle mass (a condition that can lead to sarcopenia).

To explore how to prevent this, researchers are conducting a 3- to 6-month randomized controlled trial involving adults aged 30 to 65 years with a BMI greater than 30 kg/m². Participants who are receiving GLP-1 medications will be randomly assigned to one of two groups: one group will receive the standard medication treatment alone, while the other group will receive the medication along with specific dietary guidance focused on increasing daily protein intake.

Conditions

Interventions

BEHAVIORAL

High Protein Dietary Intervention

Individualized dietary guidelines focusing on increased protein consumption to preserve muscle mass during weight loss.

BEHAVIORAL

Control (Standard Mediterranean Diet Counseling)

Standard nutritional counseling based on the Mediterranean diet pattern as part of usual clinical practice.

Sponsors & Collaborators

  • University General Hospital of Heraklion

    collaborator OTHER

  • Hellenic Mediterranean University

    lead OTHER

Principal Investigators

  • Christopher Papandreou · Hellenic Mediterranean University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-30
Primary Completion
2028-03-30
Completion
2029-01-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07495904 on ClinicalTrials.gov